SQI Diagnostics Inc.

Equities

SQD.H

CA78466B1085

Advanced Medical Equipment & Technology

Delayed Toronto S.E. 11:00:00 2023-07-12 am EDT 5-day change 1st Jan Change
- CAD -.--% Intraday chart for SQI Diagnostics Inc. -100.00% -100.00%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
SQI Diagnostics Announces Resignation of Wilmot L. Matthews as Director CI
Clive J. Beddoe Announces Resignation as Director of SQI Diagnostics Inc CI
SQI Diagnostics Announces Receipt of Intention to Enforce Security from Pivot Financial and Anticipated Voluntary Bankruptcy Filing CI
SQI Diagnostics Inc. Announces Executive Changes CI
SQI Diagnostics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2023 CI
SQI Diagnostics Inc. Extends Maturity Date of Pivot Credit Facility and Deferral of Certain Interest Payments CI
SQI Diagnostics Inc. to Focus on Development of Point of Care Products in Respiratory Health CI
SQI Diagnostics Inc. Enters into New Consulting Agreement with Looking Glass Capital Consultants CI
SQI Diagnostics Inc. Announces Four Diagnostic Products in the Pipeline CI
SQI Diagnostics Down Near 40% After Citing Liquidity, Going Concern; Reports Fiscal Q1 Loss MT
SQI Diagnostics Brief: Down Near 40% After Citing Liquidity and Going Concern As Reported First Quarter 2023 Results MT
SQI Diagnostics Inc. Reports Earnings Results for the First Quarter Ended December 31, 2022 CI
SQI Diagnostics Extends Maturity of $7.5 Million Credit Facility MT
SQI Diagnostics Inc. Extends Maturity Date of Pivot Credit Facility and Deferral of Certain Interest Payments CI
SQI Diagnostics Inc. Auditor Raises 'Going Concern' Doubt CI
SQI Diagnostics Inc. Reports Earnings Results for the Full Year Ended September 30, 2022 CI
SQI Installs Two Rali-Dx Systems in Toronto Hospitals to Fight the Growing Respiratory Health Crisis in Emergency Departments CI
SQI Diagnostics Inc. announced that it has received CAD 1.15 million in funding CI
SQI Diagnostics Completes First Tranche of Private Placement, Details Acquisition of Securities By Wilmot Matthews MT
SQI Diagnostics Plans to Raise $1 Million via Private Placement MT
SQI Diagnostics Reports Sale of Shares by Board Chairman MT
SQI Diagnostics Inc. announced that it expects to receive CAD 1 million in funding CI
SQI Diagnostics Inc. announced that it expects to receive CAD 2 million in funding from Federal Economic Development Agency for Southern Ontario CI
SQI Diagnostics Extending Maturity Date of Pivot Credit Facility and Announcing Deferral of Certain Interest Payments MT
SQI Diagnostics Inc. Extends Maturity Date of Pivot Credit Facility CI
Chart SQI Diagnostics Inc.
More charts
SQI Diagnostics Inc. is a Canada-based company that is focused on lung health. The Company is engaged in the development and manufacturing of respiratory health and precision medicine tests that run on its fully automated systems. Its clinical solutions include Rapid Acute Lung Injury Diagnostic (RALI-Dx), lung transplant diagnostics, COVID-19 testing and surveillance testing solutions. Its RALI-Dx IL-6 Severity Triage Test and the RALI-fast IL-6 Severity Triage point of care (POC) Test each help clinicians identify which patients with SARS-CoV-2 are predicted to have a severe inflammatory response and should or should not be admitted to the hospital. Its RALI-Dx delivers results from the lab in less than an hour while RALI-fast delivers results at the patient point-of-care in about 15 minutes. The Company’s TORdx LUNG Test measures inflammation at the molecular level to assess the health of the donor lung. The Company is also focused on its organ transplant pipeline of products.
More about the company
  1. Stock Market
  2. Equities
  3. SQD.H Stock
  4. News SQI Diagnostics Inc.
  5. SQI Diagnostics Closes $4.05 Million Debt Financing; Extends Maturity Date of Pivot Financial Credit Facility